Albemarle Corp. 10-Q Summary: Period Ended September 30, 1997
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1997, and the nine-month period ended on that date. Albemarle Corporation operates in the chemical industry. Following the sale of its Olefins Business to Amoco Chemical Company in March 1996, the Company's operations were realigned effective July 24, 1997, into three segments: Polymer Chemicals, Fine Chemicals, and Potassium and Chlorine Chemicals. The Company is headquartered in Richmond, Virginia.
Key Financial Metrics
| Metric | Q3 1997 | Q3 1996 | 9 Months 1997 | 9 Months 1996 |
|---|---|---|---|---|
| Net Sales ($000s) | $207,111 | $183,776 | $613,180 | $649,986 |
| Gross Profit ($000s) | $62,920 | $44,760 | $197,091 | $175,644 |
| Operating Profit ($000s) | $27,425 | $11,068 | $92,103 | $64,891 |
| Net Income ($000s) | $18,548 | $7,887 | $59,088 | $138,146 |
| Earnings Per Share | $0.33 | $0.14 | $1.06 | $2.30 |
| Cash and Equivalents ($000s) | $10,339 | $39,326 (Sep 30, 1996) | $10,339 (Sep 30, 1997) | $39,326 (Sep 30, 1996) |
| Long-Term Debt ($000s) | $38,055 | $24,406 (Dec 31, 1996) | $38,055 | $24,406 (Dec 31, 1996) |
| Gross Margin % | 30.4% | 24.4% | 32.1% | 27.0% (Reported) |
Liquidity and Cash Flow: Net cash provided by operating activities for the nine months ended September 30, 1997, was $67.7 million. Net cash used in investing activities was $71.7 million, primarily due to capital expenditures of $73.3 million. Cash and cash equivalents decreased by $3.9 million during the period to $10.3 million.
Material Changes vs. Prior Period
- Revenue: Q3 1997 sales increased 13% year-over-year due to higher shipments of flame retardants, bromine fine chemicals, and pharmaceuticals. Nine-month sales decreased 5.7% primarily because the 1996 period included two months of revenue from the Olefins Business sold in March 1996. Excluding the sold business, nine-month sales would have increased 8%.
- Profitability: Q3 operating profit increased 148% year-over-year. Nine-month operating profit increased 42% year-over-year. Gross margins improved in both periods due to better plant utilization and cost reduction programs.
- Net Income: Nine-month net income decreased significantly from $138.1 million in 1996 to $59.1 million in 1997. This decline is largely attributable to the $158.2 million gain on the sale of the Olefins Business recorded in the first nine months of 1996, which did not recur in 1997.
- Debt: Long-term debt increased from $24.4 million at year-end 1996 to $38.1 million at September 30, 1997, reflecting new borrowings to fund capital expenditures.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates that cash from operations will be sufficient to cover operating expenses, debt service, and dividends. Capital expenditures for the full year are forecasted to be slightly above 1996 levels, financed by operating cash flow and additional debt.
Product Developments:
- Saytex HP 7010: A new flame retardant for engineered plastics has received orders. A market development unit is operational, but the product is not expected to contribute to profits in the near term.
- Naproxen: Sales of this analgesic product began in Q3. However, the Company is significantly delayed in reaching sales goals due to timing issues with FDA approvals for customer applications.
Risks and Contingencies:
- Legal Proceedings: The U.S. EPA, via the Department of Justice, has threatened suit under the Clean Air Act regarding VOC emissions and PSD compliance at the Orangeburg, South Carolina plant. A penalty of $530,000 was demanded. The Company denies material violations and is in settlement negotiations.
- Environmental: The Company is subject to federal Superfund laws and may be liable for cleanup costs at hazardous waste sites.
- Foreign Currency: Strengthening of the U.S. dollar significantly reduced foreign currency translation adjustments in shareholders' equity.
Investor Verification Checklist
- Verify the impact of the one-time $158.2 million gain on the sale of the Olefins Business in 1996 when comparing year-over-year net income.
- Monitor the status of the EPA/DOJ legal proceedings regarding the Orangeburg plant and potential penalties.
- Assess the timeline for FDA approvals affecting the sales volume of the new naproxen product.
- Review the Company's capital expenditure plans and debt levels, noting the increase in long-term debt to fund growth.
- Confirm the commercial viability and profit contribution timeline for the new Saytex HP 7010 flame retardant.